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Abstract
Background: The recent reports on the decreasing susceptibility of Plasmodium falciparum to artemisinin derivatives
along the Thailand and Myanmar border are worrying. Indeed it may spread to India and then Africa, repeating the
same pattern observed for chloroquine resistance. Therefore, it is essential to start monitoring P. falciparum sensitivity
to artemisinin derivatives and its partner drugs in Africa. Efficacy of AL and ASAQ were tested by carrying out an in vivo
drug efficacy test, with an ex vivo study against six anti-malarial drugs nested into it. Results of the latter are reported
here.
Methods: Plasmodium falciparum ex-vivo susceptibility to chloroquine (CQ), quinine (Q), lumefantrine (Lum),
monodesethylamodiaquine (MDA), piperaquine (PPQ) and dihydroartemisinin (DHA) was investigated in children
(6 months – 15 years) with a parasitaemia of at least ≥4,000/μl. The modified isotopic microtest technique was used.
The results of cellular proliferation were analysed using ICEstimator software to determine the 50% inhibitory
concentration (IC50) values.
Results: DHA was the most potent among the 6 drugs tested, with IC50 values ranging from 0.8 nM to 0.9 nM
(Geometric mean IC50 = 0.8 nM; 95% CI [0.8 - 0.9]). High IC50 values ranged between 0.8 nM to 166.1 nM were
reported for lumefantrine (Geometric mean IC50 = 25.1 nM; 95% CI [22.4 - 28.2]). MDA and Q IC50s were significantly
higher in CQ-resistant than in CQ-sensitive isolates (P = 0.0001). However, the opposite occurred for Lum and DHA
(P < 0.001). No difference was observed for PPQ.
Conclusion: Artemisinin derivatives are still very efficacious in Burkina Faso and DHA-PPQ seems a valuable alternative
ACT. The high lumefantrine IC50 found in this study is worrying as it may indicate a decreasing efficacy of one of the
first-line treatments. This should be further investigated and monitored over time with large in vivo and ex vivo studies
that will include also plasma drug measurements.
Background
Artemisinin-based combination therapy (ACT) has been
deployed worldwide and is currently the only available
effective treatment for falciparum malaria [1-4]. Never-
theless, the recent reports on the decreasing susceptibil-
ity of Plasmodium falciparum to artemisinin derivatives
along the Thailand and Myanmar border [5-8] and more
recently in Kenya [9] are worrying. Indeed, artemisinin-
resistant malaria parasites at the border of Thailand and
Myanmar may spread to India and then Africa, repeating
the same pattern observed for chloroquine resistance
[10]. It is, therefore, important to document the efficacy
of currently used anti-malarials and provide early warnings
that would allow an adequate response and the contain-
ment of resistance [11]. It is essential to start monito-
ring P. falciparum sensitivity to artemisinin derivatives
and its partner drugs in Africa. This could be done by
carrying out standard in vivo drug efficacy tests
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recommended by the World Health Organization (WHO).
In addition, considering that there are no validated mo-
lecular markers related to artemisinins [6,8], ex vivo tests
may have a role as several drugs, including those in a spe-
cific ACT, can be tested at the same time [12-15].
In Burkina Faso, a new malaria treatment policy was
adopted in 2005 and was fully implemented in 2006; for
uncomplicated falciparum malaria, artesunate-amodiaquine
(ASAQ) or alternatively artemether-lumefantrine (AL) are
recommended as first-line treatments, whereas quinine is
recommended for severe malaria [16]. Efficacy of AL and
ASAQ were tested by carrying out an in vivo drug efficacy
test, with an ex vivo study against six anti-malarial drugs
nested into it. Results of the latter are reported here.
Methods
Plasmodium falciparum field isolates
The study was carried out from December 2008 to
December 2010 in Bobo-Dioulasso situated at 365 km
from Ouagadougou. The rainy season occurs from
June to October (average rainfall: 1,000 mm/year; mean
temperature >25°C) and is followed by a cold dry season
from November to February (minimum temperature 15°C)
and a hot dry season from March to May. Malaria
transmission is seasonal, from June to December. The
commonest vectors are Anopheles gambiae s.s., Anopheles
funestus and Anopheles arabiensis, and P. falciparum is
the predominant malaria parasite [17]. All children
(6 months-15 years) with fever (axillary temperature ≥
37.5°C) or history of fever in the last 24 hours were
screened for malaria infection. Children weighing 5 kg or
more with a P. falciparum mono-infection at a density be-
tween 4,000 and 200,000/μl and haemoglobin > 7 g/dL
were included in the study if their parent/guardian pro-
vided the informed consent. Venous blood (5 – 10 ml)
was collected in a tube coated with EDTA (Turumo,
Escap, Belgium) for ex vivo tests. This study was reviewed
and approved by the Institutional Ethics Committee of
Center Muraz, and was registered at ClinicalTrials.gov
(ID: NCT00808951).
Drugs
The drugs tested were from the following sources: chloro-
quine diphosphate (Sigma Aldrich, St. Louis, USA), quinine
hydrochloride (Sigma Aldrich, St. Louis, USA), lumefan-
trine (Novartis Pharma, Basel, Switzerland) piperaquine
phosphate (Sigma Tau., Rome, Italy), the active metabolite
of artemisinin, dihydroartemisinin (Sigma Tau., Rome, Italy)
and the active metabolite of amodiaquine, monodeshethyla-
modiaquine obtained from the World Health Organization
(WHO/TDR, Geneva, Switzerland). The stock solutions of
chloroquine and monodesethylamodiaquine were prepared
in sterile distilled water, in methanol for quinine and dihy-
droartemisinin, in ethanol for lumefantrine and in lactic
acid for piperaquine. A three-fold serial dilution of stock
solutions was made. The final concentrations ranged from
12.5 nM to 3200 nM for chloroquine, 7.5 nM to 1920 nM
for monodesethylamodiaquine, 13.02 nM to 3333 nM for
quinine, 1.25 nM to 320 nM for lumefantrine, 6.25 nM to
1600 nM for piperaquine and 0.25 nM to 64 nM for di-
hydroartemisinine. The distribution in the plates was done
at 50 μl per well.
Ex vivo assay
Drug sensitivity tests were performed within 24 hours of
bleeding, without culture adaptation. Blood samples
were washed three times in RPMI 1640 medium (Sigma
Aldrich, St. Louis, USA). The modified isotopic microt-
est technique [14] was used. The complete RPMI 1640
medium, i.e. supplemented with 10% of human serum
type AB (obtained from the blood bank of Souro Sanon
University hospital, Bobo-Dioulasso, Burkina Faso), genta-
micin (10 μg/ml) and tritiated hypoxanthine (Amersham,
little Chalfont, UK), was used for parasites cultivation. In-
fected erythrocytes were suspended in this medium at a
haematocrit of 1.5% and an initial parasitaemia between
0.1% and 0.5%. This suspension was then added in quan-
tities of 200 μl per well to the plates containing the drugs.
These were incubated for 48 hours at 37°C in 5% CO2.
After the incubation period, plates were frozen and
thawed to lyse the blood cells. Cultures were then har-
vested (Harvester Unifilter 96, Packard) on fibre glass
paper (reader plates Unifilter 96 Perkin Elmer). The strips
obtained were dried and transferred to a plastic bag con-
taining 30 μl of scintillation fluid (Perkin Elmer Betaplate
Scint, Wallac). The incorporation of tritiated hypoxan-
thine was measured using a scintillation Beta counter
(Perkin Elmer Wallac MicroBeta Trilux, Turku, Finland).
Data analysis and statistical methods
For parasites growth assays, the results of cellular proli-
feration were expressed as counts per minute and ana-
lysed using ICEstimator software to determine the 50%
inhibitory concentration (IC50) values [18]. The IC50 is
defined as the drug concentration able to inhibit 50% of
the uptake of 3H hypoxanthine as compared to that mea-
sured in drug-free control wells. The threshold IC50 for
ex vivo resistance was defined at ≥ 100 nM for chloro-
quine, ≥ 60 nM for monodesethylamodiaquine and ≥
800 nM for quinine [19,20]. The thresholds for lume-
fantrine, piperaquine and dihydroartemisinin are not
well established yet. Data were entered in Excel version
97 and analysed using Stata version 8.0. Results were
expressed as geometric mean IC50 values and the 95%
confidence intervals were computed. Correlation of the
IC50 values for different drugs (2 by 2) was calculated
using Spearman rank-order correlation test. The acti-
vity of monodesethylamodiaquine, quinine piperaquine,
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lumefantrine and dihydroartemisinin against chloroquine-
resistant isolates and chloroquine-sensitive isolates were
compared using the IC50 geometric means (GM). A
p value <0.05 was considered statistically significant.
Results
Ex vivo susceptibility of P. falciparum isolates was tested
for 440 samples. The culture success rate (interpretable
tests) and the IC50 geometric means of the 6 drugs
tested are summarized in Table 1. The average culture
success rate was around 85% (range: 79.3% - 86.8%). Out
of 382 samples successfully tested against chloroquine
(Geometric mean IC50 = 69.2 nM; 95% CI [60.6 - 79.1])
and quinine (Geometric mean IC50 = 162.1 nM; 95% CI
[148.3 - 177.3]), 161 (42.1%) were resistant to chloro-
quine while only 4 (1%) were resistant to quinine. Out of
377 samples successfully tested against monodeshethyla-
modiaquine (Geometric mean IC50 = 19.3 nM; 95% CI
[18.0 - 20.6]), 24 (6.4%) were resistant. The IC50 values
for lumefantrine ranged between 0.8 nM to 166.1 nM
(Geometric mean IC50 = 25.1 nM; 95% CI [22.4 - 28.2])
and that for piperaquine from 0.8 nM to 375.2 nM
(Geometric mean IC50 = 6.3 nM; 95% CI [5.9 - 6.8]).
Dihydroartemisinin was the most potent among the six
drugs tested, with IC50 values ranging from 0.8 nM to
0.9 nM (Geometric mean IC50 = 0.8 nM; 95% CI [0.8 -
0.9]). However, three isolates had much higher IC50, i.e.
19 nM, 21 nM and 38 nM (Figure 1).
The mean IC50 of the tested drugs were analysed by the
parasites’ susceptibility to chloroquine, i.e. chloroquine-
resistant (IC50 ≥ 100 nM) against chloroquine-sensitive
isolates (IC50 < 100 nM). Monodesethylamodiaquine and
quinine IC50 mean values were significantly higher in
chloroquine-resistant than in chloroquine-sensitive iso-
lates (P = 0.0001) (Table 2). However, the opposite oc-
curred for lumefantrine and dihydroartemisinin; their IC50
mean values were significantly higher in chloroquine-
sensitive than in chloroquine-resistant isolates (P ≤ 0.001).
No difference was observed for piperaquine (P = 0.382).
Cross-resistance between the six drugs is summarized
in Table 3. A significant positive correlation (by ascending
order) was found between monodeshetlyamodiaquine-
piperaquine (r = 0.14; P = 0.008), dihydroartemisinin-quinine
(r = 0.15; P = 0.002), dihydroartemisinin- piperaquine
(r = 0.27; P < 0.0001), dihydroartemisinin-lumefantrine
(r = 0.30; P < 0.0001), quinine - lumefantrine (r = 0.32;
P < 0.0001), chloroquine-quinine (r = 0.51; P < 0.0001),
monodeshetlyamodiaquine-quinine (r = 0.52; P < 0.0001)
and chloroquine-monodeshetylamodiaquine (r = 0.86; P <
0.0001). For chloroquine-lumefantrine (r = − 0.10; P = 0.03)
and monodeshetylamodiaquine-lumefantrine (r = − 0.11;
P = 0.02) the correlation was significant but negative while
for the other pair-wise comparisons no significant corre-
lation was found.
Discussion
Since the policy change in 2005 in Burkina Faso, several
studies on the therapeutic efficacy of both ASAQ and
AL were carried out [21-25]. Nevertheless, the ex vivo
susceptibility of P. falciparum to the different compo-
nents of ACT had never been tested and this is the first
study out of this kind. The prevalence of chloroquine re-
sistant isolates (CQR) was higher than that against other
drugs but lower than that reported in the same area in
2006 and estimated at 50% (Lea Bonkian, personal com-
munication), suggesting that CQ resistance may be de-
creasing, possibly following the implementation of the
new anti-malarial drug policy based on ACT. This is
plausible when considering that a similar phenomenon
has been observed in Malawi where, nine years after the
withdrawn of CQ and its replacement with sulphadoxine-
pyrimethamine, no CQR was found [26].
Despite withdrawal of chloroquine, CQR could persist
due to the use of treatments with similar chemical struc-
ture, resulting in a strong selective pressure [27]. The
positive correlation between ex vivo IC50 values of CQ
and MDA or quinine and between quinine and AQ indi-
cate cross-resistance and may explain the still high
prevalence of CQR found in this study. Such cross-
Table 1 Ex vivo susceptibility of Plasmodium falciparum isolates against chloroquine, monodeshethylamodiaquine,
quinine, lumefantrine and dihydroartemisinin
Culture
success rate
% (n/N)
IC50 mean (nM)
[95% CI]
Range (nM) Resistant
isolates (%)Minimum Maximum
Chloroquine 86.8 (382/440) 69.2 [60.6 – 79.1] 8.3 595.9 161 (42.1)
Quinine 86.8 (382/440) 162.1 [148.3 – 177.3] 10.2 950.3 4 (1.0)
Monodesethylamodiaquine 85.7 (377/440) 19.3 [18.0 – 20.6] 0.8 595.9 24 (6.4)
Lumefantrine 86.8 (382/440) 25.1 [22.4 – 28.2] 0.8 166.1 NA
Piperaquine 79.3 (349/440) 6.3 [5.9 – 6.8] 0.8 375.2 NA
Dihydroartemisinin 86.5 (381/440) 0.8 [0.8 – 0.9] 0.1 38.8 NA
Resistance threshold defined for chloroquine at 100 nM, quinine at 800 nM and monodeshethylamodiaquine at 60 nM; NA: Non applicable as the threshold is not
defined yet.
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resistance is not surprising as it has already been re-
ported by several studies [20,28,29]. Nevertheless, the
relationship between CQ and AQ efficacy is not a
straightforward one as AQ may still be effective where
CQ resistance is high [1,30-32]. This seems confirmed
by the low prevalence of AQ resistant isolates as deter-
mined by our ex vivo test. Nevertheless, almost half of
the isolates had AQ IC50 values higher than 20 nM, a
relatively high figure when considering that in Cameroun
most isolates of recurrent infection after AQ treatment
had IC50 ranging between 25.6 and 115 nM, indicating
that the threshold for AQ resistance might be lower than
the standard value of ≥ 60 nM [19]. This raises the issue of
defining appropriate drugs’ ex vivo IC50 thresholds able to
predict in vivo outcomes [19,27,33,34].
In the new malaria treatment policy adopted in Burkina
Faso, quinine is still the recommended treatment for se-
vere malaria and for any treatment failure after adminis-
tration of ASAQ or AL [16]. Only 4 isolates were found to
be resistant to quinine, an extremely low prevalence when
considering the potentially frequent use of this drug and
cross resistance with CQ. Lowering the threshold for
resistance to 600 nM [28,35,36], increased the number of
isolates classified as resistant but their prevalence remains
low, i.e. 4% (17/382). Therefore, quinine can still be con-
sidered effective in Burkina Faso though recent reports of
an increasing number of patients with recurrent infection
after ACT treatment [21,24] may result in the frequent
use of quinine as rescue treatment and higher drug pres-
sure. There is the need of regularly monitoring the suscep-
tibility of local isolates to quinine for the early detection of
quinine resistance.
The resistance threshold for lumefantrine is not estab-
lished yet but the mean IC50 (25.1 nM) found in this
study seems high compared to that (9.8 nM) reported by
a study carried out in Senegal at approximately the same
period [37]. Similarly, in Cameroon the mean IC50 for
lumefantrine was 11.9 nM in 1997 and 9.57 nM in 2003
[38]. Therefore, high lumefantrine IC50 may indicate a
decreasing susceptibility of local isolates to this drug,
though baseline data are not available, possibly explained
by the high AL use and hence drug pressure in this
urban area. Indeed, though Burkina Faso has adopted
two types of ACT as first-line treatments, ASAQ is
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Figure 1 Ditribution of IC50s values of P. falciparum ex vivo susceptibility against chloroquine (cq), monodestylamodiaquine (mda),
piperaquine (pip); quinine (qn); dihydroartemisinin (dha) and lumefantrine (lum).
Table 2 Ex vivo IC50 of Plasmodium falciparum isolates against monodeshethylamodiaquine, quinine, lumefantrine,
piperaquine and dihydroartemisinin by chloroquine susceptibility
Drug Chloroquine-resistant isolates (n = 161) Chloroquine-sensitive isolates (n = 221) P value
Chloroquine 289.8 [269.2 – 312.0)] 24.4 (22.8 – 26.1) 0.0001
Monodesethylamodiaquine 33.8 [31.4 – 36.4] 12.8 [12.0 – 13.6] 0.0001
Quinine 249.7 [223.3 – 279.1] 120.4 [107.2 – 135.2] 0.0001
Lumefantrine 21.9 [18.8 – 25.5] 27.8 [23.5 – 32.8] 0.0006
Piperaquine 6.5 [5.7 – 7.3] 6.1 [5.6 – 6.7] 0.382
Dihydroartemisinin 0.7 [0.6 – 0.8] 0.9 [0.8 – 1.0] 0.001
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mainly used in rural areas while AL in towns, including
Bobo-Dioulasso where this study was carried out. This is
also confirmed by informal discussions with local health
practitioners who stated that they mostly prescribe AL
for uncomplicated malaria. However, such hypotheses
need to be confirmed by a well-planned survey. The high
lumefantrine IC50 could also be due to technical prob-
lems related to the execution of the ex vivo test. Indeed,
lumefantrine is an amino alcohol and the drugs in this
class are not easily soluble, a characteristic that may com-
promise the reproducibility of ex vivo test results [39].
Nevertheless, the use of the ethanol as solvent in this
study should have addressed this problem so that a major
bias related to the lumefantrine solubility is unlikely.
Dihydroartemisinin-piperaquine is one of the most re-
cent ACT submitted for prequalification to the WHO [40]
and represents an additional ACT for endemic countries,
including Burkina Faso. Mean piperaquine IC50 was ex-
tremely low, only two isolates had values above 200 nM,
and similar to that observed in Uganda [41]. These results
contrast with those found in Cameroon and Kenya, where
the mean piperaquine IC50 was 39 nM and 50 nM, re-
spectively [42,43]. In addition, there was no correlation
between piperaquine and chloroquine, lumefantrine and
quinine IC50s, a weak correlation with MDA, and pipera-
quine was equally active on both CQ sensitive and resis-
tant isolates. All these elements support the use of
dihydroartemisinin-piperaquine as an alternative ACT in
Burkina Faso.
The mean dihydroartemisinin IC50 was extremely low,
indicating high susceptibility of local isolates, and in ac-
cordance with other studies carried out in sub-Saharan
Africa [36,38,44]. In addition, dihydroartemisinin IC50 was
not correlated to that of MDA while the correlation with
CQ IC50 was a negative one, also shown by its higher ac-
tivity against CQ resistant isolates as compared to sensi-
tive ones. This is reassuring when considering the threat
represented by the emergence of artemisinin resistance in
South-East Asia where, besides a delay in parasite clear-
ance, the ex vivo sensitivity of P. falciparum to artemisinin
derivatives has declined substantially over the last few
years [2,4-6,8,45,46], reaching in some regions mean
IC50 values as high 21.2 nM for dihydroartemisinin and
16.3 nM for artesunate [47]. Nevertheless, the interpret-
ation of this results should also consider the weaknesses
of the standard ex vivo tests, e.g. the 3H hypoxantine tech-
nique, in detecting artemisinin derivatives resistance [48].
Though in sub-Saharan Africa the ex vivo efficacy of arte-
misinin derivatives seems high, declining in vivo respon-
siveness of P. falciparum infections to ACT has been
observed in Kenya [9].
Conclusion
In conclusion, this study confirms that artemisinin deriva-
tives are still very efficacious and dihydroartemisinin-
piperaquine seems a valuable alternative ACT in Burkina
Faso. Similarly, both quinine and amodiaquine had a good
sensitivity profile. The high lumefantrine IC50 found in
this study is worrying as it may indicate a decreasing effi-
cacy of one the first line treatments. This should be fur-
ther investigated and monitored over time with large
in vivo and ex vivo studies that will include also plasma
drug measurements.
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